NCT02588872

Brief Summary

In this, prospective, double-blind study, patients with mild to moderate symptomatic knee osteoarthritis will be randomized to receive either a series of leukocyte poor, platelet-rich plasma or hyaluronic acid injections under ultrasound guidance. Clinical data in the form of subjective outcome measures will be collected pre-treatment and at four time intervals across a 1-year period. Synovial fluid will also collected for analysis of pro- and anti-inflammatory markers pre-treatment, and at 12 and 24 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 25, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 28, 2015

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

May 18, 2017

Completed
Last Updated

March 14, 2023

Status Verified

March 1, 2023

Enrollment Period

3.7 years

First QC Date

October 25, 2015

Results QC Date

April 12, 2017

Last Update Submit

March 12, 2023

Conditions

Keywords

platelet-rich plasmahyaluronic acid

Outcome Measures

Primary Outcomes (1)

  • International Knee Documentation Committee Score (IKDC

    This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.

    This will be assessed as a change from pre-treatment visit to 1 year post treatment.

Secondary Outcomes (4)

  • Visual Analogue Scale (VAS)

    This will be assessed as a change from pre-treatment visit to 1 year post treatment.

  • Western Ontario and McMaster Universities Arthritis Index

    This will be assessed as a change from pre-treatment visit to 1 year post treatment. 6-weeks post-treatment, 6-months post treatment, and finally at 1-year post treatment will be documented for the purpose of trending data.

  • Lysholm Knee Score

    This will be assessed as a change from pre-treatment visit to 1 year post treatment.

  • Biologic Testing of Synovial Fluid Via ELISA Assays

    Primary outcome will be change from pre-treatment to 6-month post treatment.

Study Arms (2)

Hyaluronic Acid (HA)

ACTIVE COMPARATOR

Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.

Biological: Hyaluronic Acid

Platelet-rich Plasma (PRP)

EXPERIMENTAL

Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.

Biological: Platelet-rich Plasma (PRP)

Interventions

Platelet-rich Plasma (PRP)
Hyaluronic AcidBIOLOGICAL
Hyaluronic Acid (HA)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old
  • Mild to moderate unilateral, symptomatic osteoarthritis of the knee
  • No recent (within 3 months) intra-articular intervention to the affected knee

You may not qualify if:

  • Knee instability
  • Varus/Valgus alignment \>5 degrees
  • Bilateral knee osteoarthritis
  • Systemic inflammatory arthropathy
  • Known history of anemia, coagulopathy, or present use of blood thinners

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

Related Publications (1)

  • Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. Am J Sports Med. 2017 Feb;45(2):339-346. doi: 10.1177/0363546516665809. Epub 2016 Oct 21.

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Hyaluronic Acid

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

GlycosaminoglycansPolysaccharidesCarbohydrates

Results Point of Contact

Title
Mukesh Ahuja
Organization
Rush University Medical Center

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Trials Investigator, Rush University Medical Center

Study Record Dates

First Submitted

October 25, 2015

First Posted

October 28, 2015

Study Start

August 1, 2011

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

March 14, 2023

Results First Posted

May 18, 2017

Record last verified: 2023-03

Locations